This open-label, uncontrolled clinical trial evaluated the long-term efficacy and safety of ESWT in 41 male patients (mean age 42) with chronic pelvic pain syndrome (CPPS) unresponsive to at least three prior treatments. Participants received weekly ESWT sessions for four weeks (2500 pulses at 1 bar over 13 minutes). Assessments
This 2022 review explores the applications of extracorporeal shock wave therapy (ESWT) in oncology, encompassing in vitro studies, animal models, and clinical rehabilitation. The article discusses ESWT’s potential to enhance the cytotoxic effects of chemotherapeutic agents like doxorubicin and methotrexate on osteosarcoma cell lines, as well as its role in
This 2019 meta-analysis evaluated the efficacy of extracorporeal shock wave therapy (ESWT) compared to corticosteroid (CS) injections in treating lateral epicondylitis (LE). Analyzing four randomized controlled trials, the study found that ESWT significantly improved pain intensity (VAS) and grip strength over CS injections at follow-ups beyond 12 weeks. Specifically, ESWT
This 2013 narrative review examines the application of extracorporeal shock wave therapy (ESWT) in treating tendinopathy, focusing on the differences between focused (FSWT) and radial (RSWT) modalities. The review highlights the distinct physical characteristics of FSWT and RSWT, noting that FSWT generates pressure waves that converge at a specific depth,
This 2012 randomized controlled trial assessed the efficacy of extracorporeal shock wave therapy (ESWT) in treating myofascial pain syndrome (MPS) of the trapezius muscle. Thirty patients were divided into two groups: one received ESWT (1,500 pulses per session, once weekly for three weeks), and the other underwent trigger point injections
This 2018 prospective randomized single-blinded pilot study evaluated the efficacy of high-energy (0.210 mJ/mm²) versus low-energy (0.068 mJ/mm²) extracorporeal shock wave therapy (ESWT) in 30 patients with myofascial pain syndrome (MPS) of the upper trapezius. Both groups received 1,500 pulses of ESWT once weekly for two weeks. Outcomes assessed included
This 2020 narrative review examines the application of extracorporeal shock wave therapy (ESWT) in treating various spinal pathologies. The review highlights ESWT’s potential benefits in conditions such as degenerative osteoporotic neuro-spinal pathology, heterotopic ossification due to spinal cord injury, cervical spondylosis, scoliosis, sacroiliitis, and coccydynia. ESWT is noted to upregulate
This 2021 meta-analysis evaluated the efficacy of extracorporeal shock wave therapy (ESWT) in treating myofascial pain syndrome (MPS) of the neck and shoulder. Analyzing 11 randomized controlled trials, the study found that ESWT significantly improved pain intensity (SMD = 0.67; 95% CI: 0.11 to 1.23; P = 0.02) and pressure
This 2024 notice addresses concerns regarding a 2021 randomized clinical trial comparing extracorporeal shock wave therapy (ESWT) and phonophoresis therapy for neck myofascial pain syndrome (MPS). The original study involved 40 patients divided into two groups: one receiving three weekly sessions of ESWT, and the other undergoing phonophoresis therapy with
This 2019 randomized controlled trial compared the efficacy of radial extracorporeal shock wave therapy (rESWT) and dry needling (DN) in treating myofascial trigger points (MTrPs) in the upper trapezius muscle. Sixty-five patients were randomly assigned to either the rESWT group (n=32) or the DN group (n=33), receiving three weekly treatments.
